Venture Life Group PLC Appointment of Chief Financial Officer (6279X)
01 Maggio 2019 - 8:01AM
UK Regulatory
TIDMVLG
RNS Number : 6279X
Venture Life Group PLC
01 May 2019
1 May 2019
Venture Life Group plc
("Venture Life" or the "Group")
Appointment of Chief Financial Officer
Venture Life Group plc (AIM: VLG), a leader in developing,
manufacturing and commercialising products for the international
self-care market, today announces that it has appointed Andrew
Waters, FCA, to the Board of Venture Life as Chief Financial
Officer with immediate effect.
Andrew has been working closely with the Board since February
2019 after the departure of former CFO, Adrian Crockett, earlier
this year. Andrew is a Chartered Accountant having previously
worked at PWC and then GlaxoSmithKline plc, where he spent 16 years
in various financial and business management positions. Following
this, Andrew co-founded two businesses, Cubase Consulting Ltd and
Infirst Healthcare Ltd, which he led through three successful
funding rounds, raising in excess of GBP40 million from private
equity.
Dr Lynn Drummond, Chair of Venture Life, said: "We are delighted
to welcome Andrew to the Board of Venture Life. Andrew brings a
range of skills to the team to support the ambitious plans we have
for the business over the coming years. I am confident Andrew will
be a valuable and complementary addition to the executive
team."
Disclosures required by Schedule 2(g) of the AIM Rules for
Companies
In the past 5 years, Mark Andrew Waters, aged 52, has held the
following positions where he was acting in the capacity of a
Director:
Current Directorships:
Cubase Consulting Ltd
AW Chartered Accountant
Past Directorships:
Infirst Healthcare Ltd
Infirst Healthcare Inc (USA)
Infirst Healthcare Ltd (Ireland) (formerly Immunocopea Ltd)
Respicopea Holding Ltd
Andrew Waters does not have any interest in the ordinary shares
of the Company.
There are no further disclosures to be made pursuant to Schedule
Two, paragraph (g) of the AIM Rules for Companies.
For further information, please contact:
Venture Life Group PLC +44(0) 1344 578004
Jerry Randall, Chief Executive Officer
+44(0)20 7397
Cenkos Securities Ltd (Nomad and Broker) 8900
Mark Connelly / Stephen Keys / Cameron MacRitchie
(Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
+44(0)20 3405
Alma PR 0208
Rebecca Sanders-Hewett / Hilary Buchanan / Helena
Bogle / Jessica Joynson
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in both the UK and
Italy, the Group's product portfolio includes some key products
such as the UltraDEX and Dentyl oral care product ranges, food
supplements for maintaining brain function, medical devices for
women's intimate healthcare and proctology and dermo-cosmetics for
addressing the signs of ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK these are supplied
direct by the company, outside of the UK they are supplied by the
Group's international distribution partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAZMGFDKGVGLZM
(END) Dow Jones Newswires
May 01, 2019 02:01 ET (06:01 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024
